Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients

To identify better regimens in currently available chemotherapy would be beneficial to KRAS mutant metastatic colorectal cancer (mCRC) patients because they have fewer treatment options than KRAS wild-type mCRC patients. Clinicopathologic features and overall survival (OS) of KRAS mutant and wild-ty...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Lin, Yu-Lin, Liang, Yi-Hsin, Tsai, Jia-Huei, Liau, Jau-Yu, Liang, Jin-Tung, Lin, Been-Ren, Hung, Ji-Shiang, Lin, Liang-In, Tseng, Li-Hui, Chang, Yih-Leong, Yeh, Kun-Huei, Cheng, Ann-Lii
Формат: Artigo
Язык:Inglês
Опубликовано: Public Library of Science 2014
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3913571/
https://ncbi.nlm.nih.gov/pubmed/24505265
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0086789
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы